Dr Castillo speaks with ecancer at EHA 23 about results from a prospective phase II study of venetoclax in previously treated Waldenström Macroglobulinemia (WM).

He describes the over expression of BCL2 in these cells, and the encouraging responses of a 90% response in IGM levels and reduction in blood marrow.

With venetoclax being well tolerated, Dr Castillo outlines future combinations and trial validation with larger patient cohorts.

For more in WM, watch Prof Meletios Dimopolous discuss the use of ibrutinib with chemotherapy in the iNNOVATE trial here.